Melanotan I (Afamelanotide, Scenesse)

A lab-made form of alpha-MSH that darkens skin. FDA-approved as an implant to reduce sun-triggered pain in a rare light-sensitivity disorder.

Evidence: Extensive clinical research
Half-life: Varies
Sources: 3 cited

Is melanotan I (Afamelanotide) FDA-approved?

FDA-approved (2019) as Scenesse for EPP. Unregulated "Melanotan 1" sold online isn't the approved product.

Overview

Afamelanotide makes skin cells produce more eumelanin, the dark pigment that protects against light. As Scenesse, a small implant placed under the skin by a clinician, it's approved for erythropoietic protoporphyria (EPP). In phase 3 trials, people with EPP could spend more time in light without pain. It isn't approved for cosmetic tanning.

How it works

It switches on the MC1R receptor on pigment cells, which ramps up dark melanin production without needing UV exposure.

How long does melanotan I (Afamelanotide) stay in the body?

Released slowly from the implant over days; skin darkening lasts weeks.

What it's studied for

Erythropoietic protoporphyria
Vitiligo
Other light-sensitive skin conditions

Reported side effects

Implant-site reactions
Nausea, headache
Darkening of skin and moles

Sources

The studies and prescribing labels this page is written from.